FindTrial
Sign In

Study on the use of datomycin to prevent and treat DCD donor-derived infections due to gram positive bacteria in liver transplant recipients

Study on the use of datomycin to prevent and treat DCD donor-derived infections due to gram positive bacteria in liver transplant recipients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041926
Enrollment
Unknown
Registered
2021-01-10
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gram positive bacterial infections

Interventions

1:daptomycin
2:teicoplanin

Sponsors

Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years and <= 75 years; 2. Patients who underwent liver transplantation.

Exclusion criteria

Exclusion criteria: 1. Primary graft nonfunction occurrs after liver transplatation. 2. Immediate occurrence of multiple organ failure after liver transplantation.

Design outcomes

Primary

MeasureTime frame
Culture;Postoperative graft function;—

Secondary

MeasureTime frame
Incidence rate of G+ infection;—

Countries

China

Contacts

Public ContactQiquan Wan

Third Xiangya Hospital, Central South University

13548685542@163.com+86 18073157672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026